Target intelligence / Profile preview

Poly [ADP-ribose] polymerase 12 (PARP12)

Target
PARP12
Molecular classification
Enzyme, Mono-ADP-ribosyltransferase, Interferon-stimulated gene (ISG), CCCH zinc finger protein (RNA-binding)
01

Overview

Poly [ADP-ribose] polymerase 12 (PARP12) is an interferon-stimulated, mono-ADP-ribosyltransferase enzyme, primarily located in the cytoplasm, notably at the Golgi apparatus, and can translocate to stress granules upon cellular stress. PARP12 plays key roles in antiviral defense by inhibiting viral mRNA translation, regulating inflammation via NF-κB signaling, and controlling intracellular trafficking. In cancer biology, PARP12 has been linked to chemoresistance, particularly in breast cancer, via regulation of the AKT survival pathway and protein translation. Its catalytic activity (mono-ADP-ribosylation) is crucial for many of these cellular effects. As a therapeutic target, it is less well characterized than PARP1/2 but has emerging roles in immunity and oncogenesis.

Other names
PARP12poly(ADP-ribose) polymerase 12mono-ADP-ribosyltransferase PARP12
02

Mechanism of action

Mono-ADP-ribosylation of target proteins (e.g., AKT) to regulate their function; Inhibition of protein translation by associating with the translational machinery; Regulation of intracellular trafficking through stress-induced Golgi fragmentation

03

Biological functions

Regulation of mRNA translationInhibition of viral replication (anti-viral activity)Regulation of NF-κB signaling (inflammation)Intracellular trafficking (Golgi apparatus)Regulation of AKT signalingDNA damage responseStress response (localization to stress granules)
04

Disease associations

Cancer (notably, chemoresistance in breast cancer)Infection (especially viral infection)Inflammation
05

Safety considerations

Targeting PARP12 could potentially impact normal immune responses and stress granule dynamicsImpairment of general protein synthesis and cell survival pathways (AKT regulation)
06

Interacting drugs

PARP inhibitors (general, such as PJ34 and olaparib; specific PARP12 inhibitors are not well characterized in the literature)
07

Biomarkers

Elevated PARP12 expression (noted in some cancer and infection contexts—biomarker for activation of the interferon pathway or cancer cell survival)

Beyond the preview

Go deeper on Poly [ADP-ribose] polymerase 12 (PARP12).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Poly [ADP-ribose] polymerase 12 (PARP12).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call